

Special Issue

Advancements in the Treatment of Colorectal Cancer

Message from the Guest Editor

This Special Issue spotlights advances transforming colorectal cancer (CRC) care—from prevention to survivorship—through precision and personalized medicine. Enhanced screening, risk stratification, and genomic profiling enable biomarker-driven treatment selection, while AI augments imaging, pathology, and real-time decision support. In metastatic CRC, multidisciplinary care integrates metastasectomy, ablative techniques, stereotactic radiotherapy, hepatic-arterial infusion, and advanced chemotherapy combinations tailored by tumor biology.

Translational breakthroughs include liquid biopsy, proteomics profiling, and circulating tumor DNA for minimal residual disease monitoring, resistance mapping, and dynamic therapy adaptation. The issue examines differential biology of right- versus left-sided tumors, sequencing of perioperative therapy, and the evolving roles of targeted agents (RAS/BRAF/HER2 and KRAS G12C) and immunotherapy in MSI-H/dMMR disease. Collectively, these studies define next-generation, data-driven standards poised to elevate CRC outcomes. All in all, ‘From lab evidence to clinical practices’.

Guest Editor

Prof. Dr. Andee Dzulkarnaen Zakaria

Department of Surgery, School of Medical Science & Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/251713

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).